These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26643931)

  • 21. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax
    Lamb YN
    Drugs; 2019 Aug; 79(12):1337-1348. PubMed ID: 31372959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety of influenza vaccine in clinically cured leprosy patients in China.
    Zheng Y; Chen L; Zou J; Zhu ZG; Zhu L; Wan J; Hu Q
    Hum Vaccin Immunother; 2018 Mar; 14(3):671-677. PubMed ID: 29087761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.
    Szymczakiewicz-Multanowska A; Lattanzi M; Izu A; Casula D; Sparacio M; Kovacs C; Groth N
    Hum Vaccin Immunother; 2012 May; 8(5):645-52. PubMed ID: 22418809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.
    Rivera L; Mazara S; Vargas M; Fragapane E; Casula D; Groth N
    Vaccine; 2012 Jul; 30(35):5285-92. PubMed ID: 22659448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
    Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM
    Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.
    Halasa NB; Gerber MA; Berry AA; Anderson EL; Winokur P; Keyserling H; Eckard AR; Hill H; Wolff MC; McNeal MM; Edwards KM; Bernstein DI
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):214-24. PubMed ID: 26334249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
    Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.